Terms: = Bone cancer AND CALCB, Calcitonin AND Prognosis
26 results:
1. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract] [Full Text] [Related]
2. Preoperative identification of low-risk medullary thyroid carcinoma: potential application to reduce total thyroidectomy.
Park H; Ryu HJ; Heo J; Chung MK; Son YI; Kim JH; Hahn SY; Shin JH; Oh YL; Kim SW; Chung JH; Kim JS; Kim TH
Sci Rep; 2023 Sep; 13(1):15663. PubMed ID: 37730953
[TBL] [Abstract] [Full Text] [Related]
3. cancer-related hypercalcemia and potential treatments.
Almuradova E; Cicin I
Front Endocrinol (Lausanne); 2023; 14():1039490. PubMed ID: 37033238
[TBL] [Abstract] [Full Text] [Related]
4. Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
Kesby N; Mechera R; Fuchs T; Papachristos A; Gild M; Tsang V; Clifton-Bligh R; Robinson B; Sywak M; Sidhu S; Chou A; Gill AJ; Glover A
J Clin Endocrinol Metab; 2023 Sep; 108(10):2626-2634. PubMed ID: 36964913
[TBL] [Abstract] [Full Text] [Related]
5. An Undetectable Postoperative calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.
Duval MADS; Ferreira CV; Marmitt L; Dora JM; Espíndola M; Benini AF; Camelier MV; Bulzico D; Andrade FA; Alves Júnior PA; Corbo R; Vaisman F; Zanella AB; Scheffel RS; Maia AL
Thyroid; 2023 Jan; 33(1):82-90. PubMed ID: 36222615
[No Abstract] [Full Text] [Related]
6. Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer.
Matrone A; Prete A; Nervo A; Ragni A; Agate L; Molinaro E; Giani C; Valerio L; Minaldi E; Piovesan A; Elisei R
J Endocrinol Invest; 2021 Oct; 44(10):2139-2151. PubMed ID: 33594641
[TBL] [Abstract] [Full Text] [Related]
7. Neuronal calcitonin gene-related peptide promotes prostate tumor growth in the bone microenvironment.
Zhu W; Sheng D; Shao Y; Zhang Q; Peng Y
Peptides; 2021 Jan; 135():170423. PubMed ID: 33086087
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathological features of low-grade malignant endolymphatic sac tumors.
Wang HQ; Jie L; Shi HY
Pathol Res Pract; 2018 Mar; 214(3):431-435. PubMed ID: 29482989
[TBL] [Abstract] [Full Text] [Related]
9. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract] [Full Text] [Related]
10. CD147 deficiency blocks IL-8 secretion and inhibits lung cancer-induced osteoclastogenesis.
Wang H; Zhuo Y; Hu X; Shen W; Zhang Y; Chu T
Biochem Biophys Res Commun; 2015 Mar; 458(2):268-73. PubMed ID: 25661002
[TBL] [Abstract] [Full Text] [Related]
11. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
Reagan P; Pani A; Rosner MH
Am J Kidney Dis; 2014 Jan; 63(1):141-7. PubMed ID: 24021907
[TBL] [Abstract] [Full Text] [Related]
12. Serum calcitonin may falsely estimate tumor burden in chronic hypercalcemia: a case of prostatic and multiple bone metastases from medullary thyroid cancer.
Kim HK; Bae WK; Choi YD; Shim HJ; Yoon JH; Kang HC
Thyroid; 2014 Mar; 24(3):599-603. PubMed ID: 23985043
[TBL] [Abstract] [Full Text] [Related]
13. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
Rosner MH; Dalkin AC
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
[TBL] [Abstract] [Full Text] [Related]
14. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract] [Full Text] [Related]
15. Medullary thyroid carcinoma metastatic to skin.
Nashed C; Sakpal SV; Cherneykin S; Chamberlain RS
J Cutan Pathol; 2010 Dec; 37(12):1237-40. PubMed ID: 19615004
[TBL] [Abstract] [Full Text] [Related]
16. Medullary thyroid cancer: early detection and novel treatments.
Roman S; Mehta P; Sosa JA
Curr Opin Oncol; 2009 Jan; 21(1):5-10. PubMed ID: 19125012
[TBL] [Abstract] [Full Text] [Related]
17. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
[TBL] [Abstract] [Full Text] [Related]
18. Conventional treatment of hypercalcemia of malignancy.
Davidson TG
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
[TBL] [Abstract] [Full Text] [Related]
19. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.
Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B
Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290
[TBL] [Abstract] [Full Text] [Related]
20. Atypical carcinoid tumour of the thymus: a study of eight cases.
Valli M; Fabris GA; Dewar A; Chikte S; Fisher C; Corrin B; Sheppard MN
Histopathology; 1994 Apr; 24(4):371-5. PubMed ID: 8045526
[TBL] [Abstract] [Full Text] [Related]
[Next]